WO2025214445 - TRIAZOLE COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/214445
Publication Date
16.10.2025
International Application No.
PCT/CN2025/088257
International Filing Date
10.04.2025
Title **
[English]
TRIAZOLE COMPOUND AND USE THEREOF
[French]
COMPOSÉ DE TRIAZOLE ET SON UTILISATION
[Chinese]
一种三氮唑类化合物及其用途
Applicants **
GUANGDONG YINZHU PHARMACEUTICAL TECHNOLOGY CO., LTD
GUANGZHOU YINZHU BIOMEDICAL TECHNOLOGY CO., LTD
Inventors
XU, Tengfei
HU, Shuanghua
KOU, Yuhui
LU, Zhaoshen
WANG, Meifen
TAN, Junrong
XING, Chengfeng
CHEN, Shijian
CHEN, Jiayu
ZHANG, Jing
Priority Data
202410442050.9
12.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1816 | |
| EPO | Filing, Examination, Granting | 12441 | |
| Japan | Filing, Examination, Granting | 2056 | |
| South Korea | Filing, Examination, Granting | 1848 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,901
Contact Us
Abstract[English]
The present invention belongs to the field of medicines, and specifically relates to a triazole compound, a preparation method therefor and the use thereof, and a compound as shown in formula (I), or a pharmaceutically acceptable salt. The triazole compound of the present invention has a novel structure. The cell activity test proves that the compound of the present invention has a good potential application value in anti-tumor drugs, and can provide a brand-new drug selection for developing anti-tumor and anti-inflammatory drugs.[French]
La présente invention relève du domaine des médicaments, et concerne spécifiquement un composé de triazole, son procédé de préparation et son utilisation, et un composé tel que représenté dans la formule (I), ou un sel pharmaceutiquement acceptable. Le composé triazole selon la présente invention a une nouvelle structure. Le test d'activité cellulaire prouve que le composé de la présente invention présente une bonne valeur d'application potentielle dans des médicaments antitumoraux, et peut permettre une sélection de tout nouveaux médicament pour développer des médicaments antitumoraux et anti-inflammatoires.[Chinese]
本发明属于药物领域，具体涉及一种三氮唑类化合物及其制备方法和用途，具有式(I)所示的化合物，或药学上可接受的盐；本发明的三氮唑类化合物，结构新颖。细胞活性试验证实，本发明化合物具有良好的潜在抗肿瘤药物应用价值，能够为开发抗肿瘤和抗炎药物提供全新的药物选择。